Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma

European Journal of Cancer

Volumn 49, Issue 6, 2013, Pages 1458-1466

  Tsai, Yu Chieh ^a   Yeh, Chih Hsien ^a   Tzen, Kai Yuan ^a,c   Ho, Pei Yin ^b   Tuan, Tsung Fan ^a   Pu, Yeong Shiau ^a   Cheng, Ann Lii ^a,b   Cheng, Jason Chia Hsien ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Afatinib; Bladder cancer; EGFR; HER2; Radiotherapy

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; IN VIVO STUDY; METABOLIC INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIOSENSITIZATION; TREATMENT DURATION; TREATMENT OUTCOME; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DNA BREAKS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; G1 PHASE; HUMANS; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; RANDOM ALLOCATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84875738799     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.10.020     Document Type: Article

References (38)

1. Boyle P, Levin B, editors. In: International Agency for Research on Cancer. World Cancer Report; 2008.
2. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 1 2012 10 29
3. A. Stenzl, N.C. Cowan, and M. De Santis Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur Urol 59 6 2011 1009 1018
4. C. Rodel, G.G. Grabenbauer, and R. Kuhn Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results J Clin Oncol 20 14 2002 3061 3071
5. C.M. Coppin, M.K. Gospodarowicz, and K. James Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 14 11 1996 2901 2907
6. A.C. Begg, F.A. Stewart, and C. Vens Strategies to improve radiotherapy with targeted drugs Nat Rev Cancer 11 4 2011 239 253
7. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 6 2006 567 578
8. A.J. Colquhoun, L.A. McHugh, E. Tulchinsky, M. Kriajevska, and J.K. Mellon Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo J Radiat Res (Tokyo) 48 5 2007 351 360
9. G. Bowers, D. Reardon, and T. Hewitt The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells Oncogene 20 11 2001 1388 1397
10. P. Lipponen, M. Eskelinen, S. Syrjanen, A. Tervahauta, and K. Syrjanen Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder Eur Urol 20 3 1991 238 242
11. D.E. Neal, L. Sharples, and K. Smith The epidermal growth factor receptor and the prognosis of bladder cancer Cancer 65 7 1990 1619 1625
12. F.A. Eskens, C.H. Mom, and A.S. Planting A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours Br J Cancer 98 1 2008 80 85
13. J. Bean, G.J. Riely, and M. Balak Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma Clin Cancer Res 14 22 2008 7519 7525
14. J.L. Dominguez-Escrig, J.D. Kelly, D.E. Neal, S.M. King, and B.R. Davies Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer Clin Cancer Res 10 14 2004 4874 4884
15. S.B. Maddineni, V.K. Sangar, J.H. Hendry, G.P. Margison, and N.W. Clarke Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines Br J Cancer 92 1 2005 125 130
16. A.J. Colquhoun, and J.K. Mellon Epidermal growth factor receptor (EGFR) blockade with Tarceva (TM) (Erlotinib) potentiates the antitumor effect of ionizing radiation in bladder cancer cell lines AACR Meeting Abstracts 2004 1 2004 296-d 297
17. R.J. Pietras, J.C. Poen, and D. Gallardo Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene Cancer Res 59 6 1999 1347 1355
18. S. Sato, Y. Kajiyama, and M. Sugano Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein Int J Radiat Oncol Biol Phys 61 1 2005 203 211
19. A. Chakravarti, K. Winter, and C.L. Wu Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 62 2 2005 309 317
20. M.J. Sambade, R.J. Kimple, and J.T. Camp Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts Int J Radiat Oncol Biol Phys 77 2 2010 575 581
21. M.J. Sambade, J.T. Camp, R.J. Kimple, C.I. Sartor, and J.M. Shields Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf > MEK > ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK Radiother Oncol 93 3 2009 639 644
22. K.J. Harrington, I.A. El-Hariry, and C.S. Holford Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck J Clin Oncol 27 7 2009 1100 1107
23. M. Abboud, N.S. Saghir, J. Salame, and F.B. Geara Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent lapatinib and capecitabine Breast J 16 6 2010 644 646
24. D. Li, L. Ambrogio, and T. Shimamura BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27 34 2008 4702 4711
25. V.A. Miller, V. Hirsh, and J. Cadranel Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Lancet Oncol 13 5 2012 528 538
26. K.M. Quesnelle, and J.R. Grandis Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance Clin Cancer Res 17 18 2011 5935 5944
27. C. Schuetze, A. Dorfler, and W. Eicheler Combination of EGFRMER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma Strahlenther Onkol 183 5 2007 256 264
28. M. Toulany, K. Dittmann, M. Baumann, and H.P. Rodemann Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS Radiother Oncol 74 2 2005 117 129
29. M. Krause, K. Gurtner, Y. Deuse, and M. Baumann Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors Int J Radiat Biol 85 11 2009 943 954
30. Y. Horiguchi, E. Kikuchi, and C. Ozu Establishment of orthotopic mouse superficial bladder tumor model for studies on intravesical treatments Hum Cell 21 3 2008 57 63
31. H. Blomgren, F. Edsmyr, L.V. von Stedingk, and J. Wasserman Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients Biomed Pharmacother 40 2 1986 50 54
32. Y. Yan, Y. Lu, and M. Wang Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer Mol Cancer Res 4 12 2006 971 981
33. E. Hamilton, K. Blackwell, and A.C. Hobeika Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition J Transl Med 10 2012 28
34. E.P. Rogakou, D.R. Pilch, A.H. Orr, V.S. Ivanova, and W.M. Bonner DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139 J Biol Chem 273 10 1998 5858 5868
35. K. Dittmann, C. Mayer, and H.P. Rodemann Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity Radiother Oncol 76 2 2005 157 161
36. J.E. Gonzalez, J.F. Barquinero, M. Lee, O. Garcia, and A. Casaco Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells Cancer Biol Ther 13 2 2012 71 76
37. M.A.L. Moneef, B.T. Sherwood, and K.J. Bowman Measurements using the alkaline comet assay predict bladder cancer cell radiosensitivity Br J Cancer 89 12 2003 2271 2276
38. G. Nicolle, A. Daher, and P. Maille Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation Clin Cancer Res 12 9 2006 2937 2943